When treated with opioids, such as codeine and tramadol, CYP2D6 UMs generate increased amounts of active metabolites, leading to a substantially increased risk of severe opioid toxidrome with respiratory depression even at labeled dosage regimens (27). This evidence concerns the gene CYP2D6 and Respiratory insufficiency due to muscle weakness.